We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drug companies will find more payers refusing to reimburse for cancer drugs if they don’t reduce their prices, pharmacy benefits manager Express Scripts says. Read More
Tekmira Pharmaceuticals is merging with OnCore BioPharma in an effort to develop a cure for hepatitis B and corner a potentially lucrative market. Read More
India appears intent on mending its reputation as being unfriendly to foreign drug patents, with a court temporarily blocking Cipla from marketing its own generic version of Novartis’ COPD therapy Onbrez. Read More
Dendreon has not demonstrated that its prostate cancer drug Provenge provides enough benefit over less expensive drugs to justify reimbursement, UK healthcare cost watchdog said this week. Read More
Shire will pay $5.2 billion to acquire rare disease manufacturer NPS Pharma, the latest acquisition aimed at boosting the Irish drugmaker’s rare disease portfolio. Read More
Daiichi Sankyo will pay the federal government $39 million to resolve allegations it used lavish dinners and other kickbacks to persuade physicians to prescribe more of the company’s drugs. Read More
A federal appeals court is expected to rule next month in a dispute over Actavis’s plan to pull an older formulation of its blockbuster Alzheimer’s drug Namenda from the market and replace it with a newer version. Read More
Mylan and Abbott have submitted proposed commitments to the European Commission’s competition oversight body to allay anti-competitive concerns over a proposed merger that would reincorporate Mylan in the Netherlands. Read More